对于出血患者而言,特兰胺酸的关键作用
Avery A Thompson1, Sidharth Misra2,3, Laith Ayasa4
1Program in Global Surgery and Social Change, Harvard Medical School, Boston, Massachusetts, USA.
Vox sanguinis
|November 18, 2025
概括
特兰胺酸 (TXA) 是一种重要的,廉价的药物,可以预防创伤,分娩和手术造成的致命出血. 早期服用TXA可显著降低死亡率,并且具有成本效益,即使在资源较少的环境中也是如此.
科学领域:
- 医学 医学 医学 医学 医学
- 药理学 药理学是指药理学的学科.
- 紧急医疗 紧急医疗
背景情况:
- 流血是全球健康的重大威胁,特别是在低收入和中等收入国家,有输血挑战.
- 特兰胺酸 (TXA) 是一种成熟的抗纤维解质剂,已被证明可以防止凝块分解.
研究的目的:
- 突出特兰胺酸 (TXA) 在各种出血场景中已确定的安全性,有效性和救命潜力.
- 倡导TXA的广泛实施,特别是在资源有限的环境中.
主要方法:
- 对具有里程碑意义的临床试验和证据的审查,证明TXA在创伤,产科和手术出血中的有效性.
- 分析TXA对死亡率,成本效益和不良事件概况的影响.
主要成果:
- 在创伤患者中,TXA显著降低了死亡风险,包括那些有重,穿透和头部伤害的人.
- TXA减少了产后出血导致的死亡,并降低了手术患者的死亡率和输血需求.
- 研究证实了TXA的安全性,没有显示出血栓形成或发作的风险增加.
结论:
- 特兰胺酸 (TXA) 是一种安全,有效和具有成本效益的干预措施,用于管理危及生命的出血.
- 焦点应该从进一步的试验转移到为全球实施TXA制定标准化协议.
- 在"血沙漠"中扩大TXA的访问是拯救生命和预防出血事件导致的残疾至关重要的.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care
268
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
Venous Thrombosis IV: Nursing Management
188
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
188
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Introduction to Hemostasis
13.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
13.1K
Extrinsic and Intrinsic Pathways of Hemostasis
11.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.9K


